Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Healios KK ( (JP:4593) ) has provided an update.
Healios K.K., a leading Japanese regenerative medicine biotech, is expanding its cell and gene therapy capabilities across somatic stem cell and iPSC platforms, with late-stage clinical experience for its MAPC-based invimestrocel therapy and preclinical development of gene-edited NK cell treatments. The company is positioning itself as a global player by leveraging scalable 3D bioreactor manufacturing and proprietary cell platforms to address high unmet medical needs in areas such as respiratory, neurological, oncologic, and liver diseases.
Healios has secured final approval for a roughly ¥7 billion subsidy from Japan’s Ministry of Economy, Trade and Industry to build a new Cell Processing Center within Daiwa House’s DP-Lab KOBE, dedicated to contract development and manufacturing of regenerative medicine products under GCTP and GMP standards. The facility, expected to begin operations in January 2028, will support global CDMO services and manufacture Healios’ HLCM051 product, enhancing the group’s competitiveness through AI-driven process development, automation, and export-capable infrastructure, with project-related costs booked mainly as R&D expenses and other revenue in future periods.
The most recent analyst rating on (JP:4593) stock is a Hold with a Yen349.00 price target. To see the full list of analyst forecasts on Healios KK stock, see the JP:4593 Stock Forecast page.
More about Healios KK
Healios K.K. is a Japan-based clinical-stage biotechnology company focused on regenerative medicine, developing therapies using somatic stem cells and induced pluripotent stem (iPS) cells for diseases with limited treatment options. Its pipeline includes invimestrocel (HLCM051), a multipotent adult progenitor cell therapy for conditions such as ARDS, ischemic stroke, and trauma, and HLCN061, a gene-edited iPSC-derived NK cell therapy for solid tumors, alongside a proprietary universal donor iPSC platform targeting immuno-oncology, ophthalmology, liver disease, and other severe unmet needs.
Average Trading Volume: 3,774,710
Technical Sentiment Signal: Buy
Current Market Cap: Yen49.55B
For detailed information about 4593 stock, go to TipRanks’ Stock Analysis page.